Featured ArticlesHome page featureThe Latest

Acne Vulgaris Treatment Falls Short

Featured Article

Featured Article

Acne Vulgaris Treatment Falls Short

The majority of acne patients are not likely to achieve success according to FDA guidance. Is the FDA guidance too rigorous?

More Acne News

Luciana Nofal

What is the likelihood of treatment success in patients with acne vulgaris?

According the FDA, success is defined as clear or almost clear.  The FDA recommends using the IGA grading scale. The different grades include clear (grade 0), almost clear (grade 1), mild severity (grade 2), moderate severity (grade 3), and severe (grade 4). However, there are many different scales for grading acne severity.

Data from the 2012 to 2016 NAMCS was used to determine the number of medications prescribed for outpatient visits when isotretinoin was prescribed or when isotretinoin was not prescribed and the one and only diagnosis was acne. These surveys were developed and implemented by the National Center of Health Statistics, part of the Center for Disease Control and Prevention (CDC). Results from the survey provide nationally representative yearly estimates of non-hospital-based outpatient healthcare utilization.

This study finds the majority of acne patients are not likely to achieve success according to FDA guidance. The study proposes that the FDA guidance may be too rigorous. An alternative hypothesis is that most acne patients are undertreated.

Further studies should be done to demonstrate a clinically meaningful severity difference, or minimum clinically important difference, in acne severity and these studies may help redefine acne treatment success.

How did the oral and topical medications perform? What drugs were the most efficacious at the end of 12 weeks?

The authors compared 19 oral and topical acne treatments and the results may be surprising. Read the article to find out.

  1. Adapalene and benzoyl peroxide gel 0.1%/2.5%
  2. Adapalene gel 0.1%
  3. Adapalene gel 0.3%
  4. Benzoyl Peroxide gel 2.5%
  5. Clindamycin gel 1.2%
  6. Clindamycin phosphate and benzoyl peroxide gel 1.2%/2.5%
  7. Clindamycin phosphate and tretinoin gel 1.2%/0.025%
  8. Dapsone gel 5%
  9. Dapsone gel 7.5%
  10. Minocycline foam 4%
  11. Tazarotene cream 0.1%
  12. Tazarotene foam 0.1%
  13. Tretinoin lotion 0.05%
  14. Trifarotene cream
  15. Doxycycline calcium tablet
  16. Drospirenone/ethinyl estradiol tablet
  17. Extended release minocycline
  18. Isotretinoin capsule
  19. Sarecycline tablet

 

Acne Vulgaris: The Majority of Patients Do Not Achieve Success According to FDA Guidance
Keshav Patel MS, Katherine Baquerizo Nole MD, Alan Fleischer Jr. MD

You May Also Like

Journal of Drugs in Dermatology JDD Article About Dermatological Safety of Cosmetic Products Marketed to Children: Insights on the Sephora Kids Phenomenon

Dermatological Safety of Cosmetic Products Marketed to Children: Insights on the Sephora Kids Phenomenon

| Featured Articles, Latest News, The Latest | No Comments
Harness Klotho Protein’s UV-Defying Power for Breakthrough Photoaging Repair Every day, more families are turning to beauty aisles with their kids in tow, and retailers are responding. Sephora’s new “Kids”…
Journal of Drugs in Dermatology JDD Article About Hypochlorous Acid for a Persistent Filler Nodule: A Case Report

Hypochlorous Acid for a Persistent Filler Nodule: A Case Report

| Case Reports, Featured Articles, Latest News, Medical Derm, The Latest | No Comments
Biofilms, Hard Nodules, and the Surprising Power of Hypochlorous Acid Most hyaluronic acid lumps after filler settle on their own, but a rare “delayed-onset” nodule can spell trouble—especially when it…
Journal of Drugs in Dermatology JDD Interview with Dr. Christopher Bunick: An In-Depth Interview Focusing on Atopic Dermatitis and the LEVEL UP Period 2 Data

JDD Interview with Dr. Christopher Bunick: An In-Depth Interview Focusing on Atopic Dermatitis and the LEVEL UP Period 2 Data

| Atopic Dermatitis, Featured Articles, Latest News, The Latest | No Comments
Switching from Dupilumab to Upadacitinib: Practice-Informing Evidence from LEVEL UP SWITCH This exclusive video interview with Dr. Christopher Bunick unveils the practice-changing insights of the LEVEL UP SWITCH study, designed…

Leave a Reply